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Staphylococcus aureus employs an array of virulence factors to aid in its pathogenesis. A
subset of cytotoxins termed bi-component leucocidins have been characterized as important
determinants in the host-pathogen interaction in S. aureus infections. While they have been
studied over a century, bi-component leucocidins’ complex mechanisms in pathogenesis have
not been fully elucidated. Secreted as monomers, with the exception of LukAB/GH, many
combinations of the S- (HlgA, HlgC, LukE, LukS, LukA/H) and F- (HlgB, LukD, LukF,
LukB/G) components have demonstrated cell lysis via pore formation and a magnified
proinflammatory response at sublytic concentrations. While studies have described various host
cellular receptors and therapeutic strategies to evade leucocidin binding, a common receptor for
all the leucocidins has yet to be classified. Challenges in data extrapolation have occurred due to
non-native protein expression methods and species specificity of the leucocidin components. In
turn, developing successful therapeutic strategies has proven problematic with a need for
multimodal therapy. Thus, our studies aimed to clarify the bi-component leucocidins’ cytotoxic
effects on multiple subsets of leukocytes using a native protein expression system and to identify
a novel human leukocyte receptor common to all leucocidins. Overall, combinations with HlgA

and LukE demonstrated the highest degrees of cytotoxicity against PMNs and PBMCs. Coronin
1A was discovered as a common receptor for all cognate pairs of bi-component leucocidins,
except LukAB/GH. In conclusion, our results have expanded the knowledge of the cellular
targets for leucocidin cytotoxicity and have described a common leucocidin receptor as a
potential therapeutic target against the bi-component leucocidins.
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CHAPTER I
INTRODUCTION AND REVIEW OF RELAVANT LITERATURE
1.1

Introduction
Staphylococcus aureus is a Gram-positive bacterium that causes an array of infections

from mild (e.g., skin and soft tissue infections (SSTIs)) to severe (e.g., necrotizing pneumonia)
[1-3]. Due to its vast repertoire of virulence factors, S. aureus subverts the innate and adaptive
immune systems by various mechanisms [1,3-6]. With the development of increased antibiotic
resistance, S. aureus has become more challenging to successfully treat in both
immunocompromised and healthy individuals [3,5,7-15]. Thus, focus has primarily shifted to
targeting virulence factors as a therapeutic approach either in conjunction with antibiotics or as
a standalone modality [1,4,7,10,11,13-15].
Of S. aureus’s virulence factors, the bi-component leucocidins are considered essential
toxins in the pathogenesis of S. aureus infection. The toxins are termed bi-component, because
the interaction of the S- (HlgA, HlgC, LukE, LukS, LukA/H) and F- (HlgC, LukD, LukF,
LukB/G) components is necessary to promote an inappropriate, non-protective immune
response. Bi-component leucocidins are classified as beta-barrel pore-forming cytotoxins that
disrupt functions of multiple cell types, including leukocytes and erythrocytes [13,14].
Immunomodulatory effects have been demonstrated through host cell lysis and by
enhancement of the proinflammatory response at sublytic concentrations; however, a
comprehensive analysis of the cognate and noncognate receptor-ligand pairs on all leukocyte
1

subsets have yet to be described [1,8,10]. The discovery of host cellular receptors of bicomponent leucocidins has led to the study of novel therapeutic approaches focused on
blocking the respective receptors [9,16]. Due to the species specificity of the leucocidins and
their associated receptors, a complete picture of their role in S. aureus’s pathogenesis has yet
to be elucidated.
1.2
1.2.1

Bi-component leucocidin structure and function
Toxin discovery summary
Leucocidins were discovered over a century ago. The term leucocidin originated in 1894

when Van de Velde first described S. aureus’s leukocytic effect in a study using leukocytes of
rabbits. Much of the early 20th century was focused on studying the broad leukocytic and
hemolytic functions of the organism. Further delineation of alpha-hemolysin and leucocidin as
separate toxins occurred in 1932 by Panton and Valentine; thus, changing the term leucocidin to
Panton-Valentine leucocidin (PVL) [1,17]. However, at that time, it was still unclear that
multiple leucocidins were encoded within the S. aureus genome. The bi-component nature of
leucocidins was discovered by Woodin. Via chromatography, he discovered two proteins
compromising the leucocidin, which he termed ‘S’ for slow and ‘F’ for fast as discerned by their
elution properties. Gamma hemolysin was first identified by Smith and Price in 1938, and its
lytic activity on both erythrocytes and leukocytes was further described by Fackrell and
Wiseman. LukED was first identified in 1998; however, later studies concluded the original
sequence to be an anomaly. Thus, the sequence denoted by Morinaga and others was considered
the primary sequence. LukAB/HG was first characterized in 2010. Because two different groups
characterized the same leucocidin, two nomenclatures were created [17]. Through the studies
conducted in the 20th century and early 21st century, we currently recognize 5 S-components
2

(HlgA, HlgC, LukE, LukS-PV, LukA/H) and 4 F-components (HlgB, LukD, LukF-PV,
LukB/G) in human S. aureus strains [1].
1.2.2

Genomic structure
The gamma hemolysins (HlgA, HlgC, and HlgB) and LukAB/HG are part of the core

genome, while LukED and PVL are located on a pathogenicity island (vSaβ) and a temperate
phage (ϕSa2), respectively. The S and F subunits are transcribed in pairs, utilizing one promoter
per pair (i.e., lukED, lukAB/HG, and lukSF-PV). The gamma hemolysins are the exception,
where hlgC and hlgB comprise a single operon; however, hlgA transcription occurs separately
[17].
The presence of the toxins on the S. aureus genome vary by strain. The gamma
hemolysins have been estimated to be encoded in 99% of the strains [8]. LukED has been
identified in approximately 88-99% of MRSA strains globally. Further, while PVL is estimated
to only be present in 5% of all S. aureus strains, the genes are encoded in community acquired
MRSA strains at a much higher frequency of about 85% [7].
1.2.3

Protein sequence redundancy
All the leucocidin components are of similar protein size between 30-40 kDa. In relation

to protein sequences, the S-components (LukE, HlgA, HlgC, and LukS-PV) exhibit highly
similar sequences with greater than 70% homology. The F-components (LukF, HlgB, and LukFPV) share a similar percentage of sequence homology. When comparing F- and S-component
protein sequences, an approximately 30% sequence homology has been noted. Analyzing the
sequence of LukAB/HG revealed a sequence homology of 33-40% in comparison to their
respective subunits [7].
3

1.2.4

Pore construction
After transcription, F and S subunit proteins form as monomers and are water-soluble. In

this phase, each subunit alone is not cytotoxic. Following individual secretion, the F or S subunit
binds to its host cellular receptor and the other respective subunit binds to the subunit attached to
the receptor. The S subunit appears to be the primary component interacting with the cellular
receptor; however, HlgB was found to elicit the host interaction for the gamma hemolysins on
erythrocytes [7,17]. Recently, it has been proposed that LukF-PV and LukS-PV have individual
cellular receptors [7]. The F and S subunits oligomerize in an alternating sequence, which is
termed an octameric prepore. A mature octomeric pore is created when the stem domain inserts
into the membrane of the host cell which leads to osmotic cell lysis and ultimately cell death
[9,10,17].
Although evidence suggests this method as the primary means of pore formation,
LukAB/HG has been reported to secrete as a heterodimer instead [1,7,8,17]. The final octameric
structure was found to have unique salt bridges which is different from the other leucocidins as
well [18,19].
1.2.5

Sublytic concentration immunomodulatory effects
While bi-component leucocidins are known for their cytolytic properties, these toxins

have also exhibited immunomodulatory effects at sublytic concentrations. PVL has been the
primary focus of these studies. IL-1β induction and inflammasome activation have been
demonstrated by PVL on human alveolar macrophages, resulting in infiltration of neutrophils via
chemotactic factors [1]. Further studies revealed all leucocidins induce IL-1β induction through
K+ efflux [4].
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Further, human polymorphonuclear leukocytes (PMNs) are affected by sublytic
concentrations of leucocidins. Human PMNs are primed by sublytic concentrations of LukED
and PVL further enhancing the host proinflammatory response. LukAB/HG and PVL enhance
CD11b receptor expression on PMNs in addition to promoting extracellular trap production [1].
LukAB/GH has also been noted to aid in pathogenesis after S. aureus is phagocytized by
neutrophils [8].
Pore formation alone activates Caspase-1 which triggers pyroptosis along with secretion
of proinflammatory cytokines, including IL-33, IL-18, and IL-1β. Thus, in theory, all leucocidins
promote a proinflammatory response [8].
1.2.6

Lytic concentration immunomodulatory effects
Each F and S subunit pair lyses leukocytes and erythrocytes to varying degrees; therefore,

although leucocidins exhibit structural redundancy, their functions are unique [8]. Table 1
summarizes the currently published pairs and their respective human cell targets for lysis. While
most early studies focused on the cotranscribed pairs (i.e., cognate pairs), more recent studies
have described the lytic abilities of non-cotranscribed pairs (i.e., noncognate pairs) [1,17].
As a result of cellular destruction, a proinflammatory response occurs. IL-8, leukotrienes,
and histamine have been noted to release when PVL lyses leukocytes. Upon lysis, cytoplasmic
contents containing damaging enzymes are also released, producing an additive effect on the
proinflammatory response [17].
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Table 1.1

Characterized bi-component leucocidin pairs cytotoxic effects on human
leukocytes

Bi-component pair
PVL (cognate)
LukED (cognate)

HlgAB (cognate)
HlgCB (cognate)
LukAB/GH (cognate)

HlgA/LukF-PV (noncognate)
HlgA/LukD (noncognate)

Target cell
PMN
PMN
Monocytes and macrophages
T cells
Natural Killer (NK) cells
Dendritic cells (DC)
PMN
Erythrocytes
PMN
PMN
Monocytes and macrophages
DCs
Erythrocytes
Neutrophils
Erythrocytes

Table adapted from [1].

1.3
1.3.1

Host receptor interactions of bi-component leucocidins
Characterized cellular receptors
With the discovery of the human cellular receptors for the bi-component leucocidins,

further insight into the toxins’ role in S. aureus pathogenesis has been achieved. Most receptors
characterized thus far are specific to one or a few leucocidin combinations. The first receptor
discovered for the bi-component leucocidins was CCR5. This G protein coupled chemokine
receptor was specific for LukED on dendritic cells, macrophages, and lymphocytes. The Scomponent, LukE, bound to CCR5 directly. Since CCR5 has been implicated in the pathogenesis
of HIV, the drug maraviroc, was used to block the receptor binding of LukE to CCR5. However,
there was noted to be potential for other LukED receptors, because the combination is known to
lyse PMNs and monocytes independently of CCR5 [1, 11, 17]. Further, LukED receptor studies
reported CXCR1 and CXCR2 as additional chemokine receptors for LukE [10]. Like LukED,
6

HlgAB has demonstrated binding to CXCR1, CXCR2, and CXCR4 via HlgA. CCR2 was also
noted as an HlgA receptor [4].
Through an antibody-based approach, the next receptors described were C5aR and C5L2.
It was reported that LukS-PV binding to C5aR was inhibited by the antibodies. LukS-PV has
been shown to block complement activation via C5aR [1, 11]. Later, C5aR and C5L2 were
discovered as receptors for HlgCB as well [10, 16].
Diverging from chemokine receptors, LukAB/HG was reported to bind as a dimer to the
integrin CD11b [11]. Multiple functions of CD11b have been documented including chemotaxis,
adhesion, and phagocytosis [11]. Like the previously mentioned receptors, CD11b has also been
noted as a receptor for LukS-PV [23].
In contrast to S subunit receptor interaction, LukF-PV has been shown to bind to CD45
directly. CD45 interaction with LukF-PV occurred independently of LukS-PV. The expression of
this human receptor has been noted on the surface of every hematopoietic cell. Discovering a
receptor specific to an F subunit indicated the need for further evaluation of the human bicomponent leucocidin receptor repertoire [16].
For erythroid cells, one human receptor, the Duffy antigen receptor for chemokines
(DARC), has been identified for the hemolytic combinations of LukED and HlgAB. Again, the
S- components LukE and HlgA were responsible for receptor interaction. The lysis of human
erythrocytes via DARC has been proposed to be important for S. aureus iron acquisition via
hemoglobin [3,10].
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Table 1.2

Summary of identified leucocidin receptors

Cellular receptor
C5aR1/C5aR2

Binding subunit
LukS-PV
HlgC

CD11b

LukS-PV
LukAB/HG

CD45

LukF-PV

CCR5

LukE

CXCR1/CXCR2

LukE
HlgA

CXCR4

HlgA

CCR2

HlgA

Duffy antigen receptor for
chemokines (DARC)
Table adapted from [10].
1.3.2

HlgA
LukE

Receptor cellular expression
Neutrophils
Monocytes
Macrophages
Neutrophils
Monocytes
Macrophages
Dendritic cells
T cells
B cells
Neutrophils
Natural killer cells
Monocytes
T cells
Monocyte
Macrophages
Natural killer cells
Neutrophils
Monocytes
Macrophages
Natural killer cells
Neutrophils
Monocytes
Natural killer cells
Monocytes
Macrophages
T cells
Neutrophils
Erythrocytes

Receptor interaction domains and inhibitory outcomes
Although various leucocidin combinations bind to identical cellular receptors, the

interaction domains have been discovered to be unique for the respective S-components thus far.
For example, PVL has been determined to bind to C5aR1 through the second extracellular loop,
while HlgCB interacts with the first and third extracellular loops. In addition, DARC receptor

8

interaction has been proven to have both similar and different domains with LukED and HlgAB.
LukED appeared to interact with a unique N-terminal receptor residue not involved with HlgAB
binding; however, both utilize sulfated N-terminal tyrosine residues [10]. Lastly, differing from
LukS-PV binding to CXCR1/CXCR2, LukE has been reported to interact with loop L3 glycine
and proline residues [9].
Because the bi-component leucocidin components interact with various immunological
receptors, the interactions have been reported to block specific immunological substrates. CCL3,
CCL4, and CCL5 have all been demonstrated to be inhibited by LukE’s interaction with CCR5.
Further, as the CXCR1/2 substrate, IL-8 has been reported to be blocked by HlgA on PMNs.
HlgA has also been discovered to inhibit the activation of macrophages via MCP-1 which is the
CCR2 substrate. Lastly, C5aR1 signaling has been proven to be interrupted by HlgC and LukSPV [4].
1.4
1.4.1

Therapeutic approaches
Receptor inhibition utilization
With the discovery of multiple myeloid and erythroid receptors of the bi-component

leucocidins, treatment modalities utilizing antibodies or othcoer biologics to inhibit receptor
binding of bi-component leucocidins have been proposed as alternative strategies [9].
Several antibodies have been described that block the leucocidin-receptor interaction.
Rouba et al. tested two antibodies, ASN-1 and ASN-2, alone and in combination, termed
ASN100, to analyze their ability to inhibit leucocidin cytotoxicity. ASN100 was noted to inhibit
all cognate pairs from lysing leukocytes [24]. In addition to ASN100, Rouba et al. demonstrated
cross-reactivity of the Hla-LukF-LukD-HlgB antibody. In vitro assays revealed the single
antibody protected leukocytes from lysis. When challenged with HlgAB and HlgA/LukD, the
9

Hla-LukF-LukD-HlgB antibody also prevented hemolysis [13]. Another antibody called YG8-2
was shown to also prevent the cytotoxic effects on human leukocytes by cognate leucocidin
pairs. Using murine models, the authors reported increased survival in a bacteremia model [15].
In addition to antibody inhibition, other biologics have been proposed as treatment
options. As mentioned previously with the discovery of CCR5 as a human cellular receptor for
LukE, maraviroc, an HIV drug, was demonstrated to inhibit LukED cytotoxicity in a CCR5dependent manner [11]. With this discovery, novel biologic agents have been noted to inhibit
cytotoxin interaction with host cellular receptors. For example, centyrins have been proposed to
block leucocidins from binding to their targeted receptors [5,6]. Originating from human protein
tenascin-C as small proteins, centyrins were classified as small proteins that inhibit the
cytotoxicity of the bi-component leucocidins on leukocytes and erythrocytes. The authors
recommended fusing centyrins with antibodies to create a therapeutic alternative [6]. Using
leucocidins lacking a glycine-rich motif in the stem domain, Reyes-Robles et al. reported that
dominant-negative leucocidins impair mature pore production with their wild type counterparts;
thus, inhibiting human PMN cytotoxicity as well as lethality in mice [14].
1.4.2

Attenuated vaccination
Studies have identified potential strategies to create successful attenuated vaccines. The

challenge presented is to provide broad protection against all leucocidins; thus, a multivalent
vaccine is likely necessary. Aman et al. mutated LukS-PV at three sites: T28F, K97A, and
8209A. With these mutations, LukS was unable to complete pore formation when presented with
LukF-PV and HlgB, and PMNs were not lysed. Using a mouse model, cross neutralization was
observed except for LukAB/HG [1].
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Another vaccine candidate was developed using a mutant of LukAB/HG defined as
LukAD39ALukBR23E. Attenuation was achieved when PMNs were challenged. In addition, this
study reported antibody protection in PMNs and THP-1 monocytes against LukAB. Using a
polyclonal antibody cocktail of Hla, LukS-PV, LukF-PV, and anti-LukAB polyclonal antibodies,
culture supernatants were neutralized. Therefore, the authors emphasized the need for a
multivalent toxoid vaccine for the bi-component leucocidins [21].
Hernandez et al. defined immunogenic B-cell epitopes to identify a potential subunit
vaccine. By using a phage display system, HlgA and LukS-PV genes were fragmented and
ligated in a custom system called pComb-Opti8. With this methodology, they described an 11amino-acid peptide probe conserved in four leucocidin subunits. A murine model was
immunized with the peptide which displayed a cross-reactive IgG response. Thus, the authors
proposed a new strategy to identify successful bi-component leucocidin subunit vaccine
candidates [25].
1.5

Objective and significance of this dissertation
The mechanisms by which staphylococcal bi-component leucocidins aid in S. aureus’s

pathogenesis are still poorly understood despite research efforts for over a century. As S. aureus
develops increased resistance to currently available antibiotics, it is imperative to enhance our
knowledge of its pathogenesis to develop alternative biologic agents and vaccines against the
organism’s virulence factors. With these studies, we aimed to further characterize the bicomponent leucocidins role in human S. aureus infections.
Our first objective was to characterize the bi-component leucocidins’ cytotoxic effects on
major leukocyte subsets and erythrocytes utilizing native protein derived from S. aureus. While
various studies have been conducted analyzing leucocidin cytotoxicity, no study, to our
11

knowledge, has completely evaluated all human leukocyte subsets with cognate and noncognate
pairing of native S. aureus protein cytotoxicity effects. While generating protein from an E. coli
vector system is possible in the analysis of leucocidin cytotoxicity, the tagging may alter the
native structure of the protein. Therefore, to effectively evaluate the cytotoxic effects of
leucocidins on human leukocyte subsets and erythrocytes, it is imperative to use human blood
and native protein.
To identify a novel receptor for the bi-component leucocidins, we proposed to use farwestern blotting as a method to identify protein-protein interactions between the bi-component
leucocidins and primary human leukocytes. For the protein-protein interactions to be accurately
deciphered, the methodology must be perfected. Hence, our second objective was to evaluate the
proper methodology to identify a specific cellular receptor.
By utilizing our enhanced far-western blotting methodology, our third objective was to
identify a novel human cellular receptor of the bi-component leucocidins. While multiple
receptors have been described, a common receptor for all the leucocidins has yet to be
discovered. Identifying a common receptor would aid in our ability to develop an alternative
therapeutic approach to inhibit binding of bi-component leucocidins.
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CHAPTER II
COMPREHENSIVE ANALYSIS OF CYTOTOXICITY AND CELLULAR SPECIFICITY OF
STAPHYLOCOCCAL CYTOTOXINS TOWARD HUMAN LEUKOCYTES
2.1

Abstract
Among many virulence factors produced by Staphylococcus aureus, staphylococcal α-

hemolysin and bi-component leucocidins have gathered much attention for their potent
cytotoxicity toward whole leukocyte populations. The bi-component leucocidins display cellular
cytotoxicity by hetero-oligomerization among F- and S-component toxins with genes located
either adjacent in the S. aureus genome (cognate pair) or non-adjacent (noncognate pairs).
However, information on the cytotoxicity and cellular specificity of the bi-component
leucocidins is largely limited to the cognate pairs or conflicted among the studies, presumably
due to the difference in experimental conditions. In this study, we generated recombinant
staphylococcal α-hemolysin and bi-component leucocidins in a native S. aureus background and
comprehensively tested the cytotoxicity and cellular specificity of cognate and noncognate pairs
using human leukocytes. Consistent with previous findings, polymorphonuclear neutrophils and
monocytes were susceptible to nearly all combinations of bi-component leucocidins and αhemolysin. Importantly, HlgA paired with an F-component of leucocidin (HlgB, LukD, and
LukF) showed cytotoxicity to nearly all leukocyte subpopulations including monocytes, T cells,
B cells, and NK cells. Given the high conservation of HlgA, HlgB, and LukD in S. aureus
clinical isolates and universal cytotoxicity to human leukocytes, these toxins may have more of a
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broad impact on the pathogenesis of S. aureus compared to the other known leucocidins. Further
studies are necessary to characterize the specific receptor and mechanism of these toxin
interactions for the development of effective therapeutics.
2.2

Introduction
Staphylococcus aureus is a prominent pathogen that seriously affects human health in

both hospital and community settings. Approximately 30% of the population is asymptomatically
colonized with this organism. However, upon invasion to deeper tissues, it causes diseases
manifesting as mild skin infections to more severe systemic infections such as sepsis, necrotizing
pneumonia, and infectious endocarditis [10,18]. This versatile pathogenesis is largely attributed
to a multitude of virulence factors that aid in evasion from innate and adaptive immunity [8,26].
Among the many virulence factors of S. aureus exists a group of cytotoxins capable of killing
host immune cells, the central mechanism of host defense against invading pathogens [8,27-29].
Thus, staphylococcal cytotoxins have been considered the major virulence factors of S. aureus
[18]. There are three types of cytolytic toxins produced by S. aureus: 1) the short amphiphilic
peptides such as delta toxin and phenol soluble modulins (PSMs); 2) a monomeric alpha
hemolysin; 3) and bi-component leucocidins such as gamma hemolysins and leucocidins [30,31].
Based on migration in chromatography, the bi-component leucocidins consist of F- (fast) and S(slow) components. Thus far, five S-component subunits (HlgA, HlgC, LukA, LukE, LukS) and
four F-component subunits (HlgB, LukB, LukD, LukF) have been characterized in S. aureus
[6,10,16]. Interestingly, pairs of F- and S-component toxin genes are adjacently located next to
each other in the S. aureus genome such as lukAB, lukDE, lukFS, and hlgABC [17]. The
cytotoxicity of bi-component leucocidins is produced by hetero-oligomerization between F- and
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S-components encoded by genes located either adjacent in the S. aureus genome (cognate pair)
or non-adjacent (noncognate pair) [32].
While the cytotoxicity of delta toxin and PSM is caused by non-specific insertion of these
toxins into the cellular membrane, the cytotoxicity of bi-component leucocidins is generally
initiated by binding of an S-component to a cellular receptor on the target cell which recruits
secondary binding of an F-component subunit, resulting in hexa- or octameric oligomerization of
alternating F- and S- toxin components to form a  barrel pore forming ring-like structure [1,7].
Recent studies demonstrated that the majority of bi-component leucocidins bind to the families
of complement and chemokine receptors. Both HlgCB and LukSF-PV target the complement
component C5a receptors (C5aR1 and C5aR2) which are highly expressed in neutrophils and
monocytes. Correspondingly, HlgCB and LukSF-PV are highly toxic to neutrophils and
monocytes [28,33]. LukED targets CXCR1/2 and CCR5 chemokine receptors that are highly
expressed in neutrophils/monocytes and T cells, respectively. Correspondingly, LukED showed
cytotoxicity to neutrophils, monocytes, and T cells [2,34]. Although the information on the
cytotoxicity and cellular specificity of the cognate pairs has rapidly expanded in recent years,
there are some discrepancies in the literature regarding the cytotoxicity and cellular specificity of
the cognate pairs, largely due to the difference in experimental conditions. It is noteworthy that
the majority of cellular receptors for bi-component leucocidins are chemokine receptors whose
expression can be greatly modulated by lipopolysaccharide (LPS), and most studies have used
recombinant toxins expressed in E. coli systems which can be easily contaminated with LPS
[14]. Thus, the aim of this study was to generate recombinant staphylococcal bi-component
leucocidins and α-hemolysin in the native S. aureus background to prevent LPS contamination
and perform a comprehensive analysis of cytotoxicity and cellular specificity using human
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leukocytes. Expanding the knowledge of cytotoxicity and cellular specificity of staphylococcal
cytotoxins is important for a better understanding of their role in the pathogenesis of S. aureus
infection. In turn, a more successful vaccine or treatment may be able to be developed.
2.3
2.3.1

Materials and methods
Construction of protein expression vectors
All primers used in this study are listed in Table 2.1. The promoter and signal peptide

sequence of the eta gene was amplified by polymerase chain reaction (PCR) using primers
(ETAF-SalI or ETA-EcoRI/ETAsigSOER). The mature cytotoxin genes without the signal
peptide sequence were amplified by PCR using a forward primer containing the overlapping
sequence of the ETAsigSOER primer for Splicing by Overlap Extension (SOE) PCR and a
reverse primer in-frame fused with the 6X Histidine sequence in the pMK4 plasmid. The PCR
and SOEing PCR reactions were carried out in a thermocycler (Applied Biosystems) for 30
cycles consisting of 1 min at 94°C, 1 min at 58°C, and 1 min at 72°C using a reaction buffer
recommended by the supplier (50 mM KCl, 10 mM Tris-Cl, pH 8.3, 2.0 mM MgCl2, 0.01%
(wt/vol) gelatin). Deoxyribonucleotides at a final concentration of 200 µM and Taq polymerase
(Applied Biosystems) at 2.5 units were used per reaction. The PCR products were analyzed by
1% agarose gel electrophoresis. The SOEing PCR products were cleaned up by a PCR
purification kit (Qiagen) and digested by EcoRI or SalI and BamHI enzymes. Digested SOEing
PCR products were ligated into the corresponding sites in the pMK4 plasmid. Ligated products
were transformed into E. coli DH5α, followed by S. aureus RF122 toxin-free strain using
electroporation [35].
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Table 2.1

Primers for multiplex PCR to detect virulence factors and genetic markers of MGE

Primer name
ETAF-SalI
ETAF-EcoRl
ETAsigSOWR
ETAsigHlgAF
HlgAR BamHI
ETAsigHlgBF
HlgBR BamHI
ETAsigHlgCF
HlgCR BamHI
ETAsigLukDF
LukDR BamHI
ETAsigLukEF
LukER BamHI
ETAsigLukFF
LukFR BamHI
ETAsigLukSF
LukSR BamHI
ETAsigHlaF
HlaR BamHI

2.3.2

Sequence (5'-3')
GGA TGT CGA CAA ATA TCA ACG TGA GGG C
GGATGAATTCAAATATCAACGTGAGGGC
TGCTTTTGCATGGTTTTTTTGCATC
GCAAAAAAACCATGCAAAAGCAGAAAATAAGATAGAAGATATCGGC
GCGCGGATCCTTACTTAGGTGTGATGCT
AAAAACCATGCAAAAGCAGAAGGTAAAATAACACCAGTC
GCGCGGATCCCTATTTATTGTTTTCAGTTTC
AAAAACCATGCAAAAGCAGCTAACGATACTGAAGAC
GCGCGGATCCTCAATTCTGTCCTTTCAC
AAAAACCATGCAAAAGCAGCTCAACATATCACACCT
GCGCGGATCCTTATACTCCAGGATTAGT
AAAAACCATGCAAAAGCAAATACTAATATTGAAAATATTGGT
GCGCGGATCCTTAATTATGTCCTTTCAC
AAAAACCATGCAAAAGCAGCTCAACATATCACACCT
GCGCGGATCCATCTGTTTAGCTCATAGG
AAAAACCATGCAAAAGCAGATAACAATATTGAGAATATT
GCGCGGATCCTCAATTATGTCCTTTCAC
AAAAACCATGCAAAAGCAGCAGATTCTGATATTAAT
GCGCGGATCCTCATTTCTGAAGTTATCG

Purification of recombinant staphylococcal cytolytic toxins
All S. aureus strains harboring a cloned plasmid were cultured in brain heart infusion

(BHI) broth supplemented with chloramphenicol (10 µg/ml) for 18 hours at 37oC with shaking at
200 rpm. The culture supernates were harvested by centrifugation at 12,000 g and sterilized by
filtration with a 0.45 µM porous filter (Corning). For checking protein expression level, one
milliliter of culture supernate was precipitated using 10% (w/v) trichloroacetic acid. For
purifying recombinant proteins, culture supernates were conditioned to a binding buffer (50 mM
Tris-Cl pH 8.0, 5 mM imidazole, 100 mM NaCl, 0.1 mM EDTA) and loaded onto a Ni-column
(Novagen). After washing with a binding buffer, proteins were eluted with an elution buffer (50
mM Tris-Cl pH 8.0, 300 mM imidazole, 50 mM NaCl, 0.1 mM EDTA). The buffer was changed
to 2 mM HEPES buffer using a PD-10 desalting column (GE Healthcare), quantified by
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calculating the extinction coefficient at 280 nm deduced from the protein sequence, and stored at
– 20oC until used.
2.3.3

Isolation of human leukocytes
All experiments using human blood were reviewed and approved by the Institutional

Review Board at Mississippi State University (IRB, 12-041), and a written informed consent was
obtained from all volunteers. Blood was obtained from healthy volunteers aged 18 – 40 years of
age by venipuncture. Whole leukocytes were isolated by lysing red blood cells using ammonium
chloride potassium (ACK) buffer (Thermo Fisher Scientific). Polymorphonuclear cells (PMNs)
were isolated by gradient centrifugation using PolymorphPrep (Axis-Shield). Peripheral blood
mononuclear cells (PBMCs) were isolated by gradient centrifugation using Histopaque-1077
(Sigma-Aldrich). The isolated cells were adjusted to 1×106 cells/ml in RPMI medium
(Invitrogen) 200 µL of PMN or PBMC suspension was added to a 96-well plate (Corning).
2.3.4

Cytotoxicity assay
An equal concentration of S-component (HlgA, HlgC, LukE, LukS) and F-component

(HlgB, LukD, LukF) or Hla ranging from 0.1 to 500 nM was added to the 96-well containing
whole leukocyte, PMNs, or PBMCs (1×106 cell/well). The plate was incubated at 37oC in 5%
CO2 for 1 hour. To measure the lactate dehydrogenase activity, cells were pelleted by
centrifugation at 1,000 g and culture supernates were removed and added to wells containing 50
µL of LDH reagent (Clontech) and incubated for 10 min at room temperature. Fluorescence was
measured using SpectraMax (Molecular Devices) with an excitation at 550 nm and emission at
580 nm. Data was normalized to 100% lysis of PMN or PBMC by 0.2% (w/v) Triton X-100.
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To determine cellular specificity of staphylococcal cytotoxins, an aliquot of Hla or Scomponent (HlgA, HlgC, LukE, LukS) and F-component (HlgB, LukD, LukF) at 100 nM was
added to the 96-well containing PMNs or PBMCs (1×106 cell/well). The plate was incubated at
37oC in 5% CO2 for 30 min. Following incubation, cells were labeled with monoclonal antibody
specific to CD3 T cells, CD4 T cells, CD8 T cells, CD14 monocytes, CD19 B cells, and CD56
natural killer (NK) cells. All antibodies were conjugated with allophycocyanin (Thermo Fisher
Scientific). After labeling with antibody, propidium iodide (PI) solution (0.5 mg/ml) was added
and incubated for 15 min at 4oC. Viability of specific leukocyte subpopulations was determined
using a NovoCyte flow cytometer.
2.3.5

Cytolytic toxin binding assay
To determine the binding of the bi-component leucocidins to human PMNs and PBMCs,

the bi-component leucocidins were biotinylated using EZ-Link Sulfo-NHS-LC-Biotin (Thermo
Scientific) according to the manufacturer’s instructions. The biotinylated protein at 100 nM was
incubated with human PMNs or PBMCs for 1 hour. After washing with HBSS, cells were further
incubated with streptavidin conjugated with FITC (1µg/ml) for 30 min on ice. After washing
with HBSS, cells were analyzed using a NovoCyte flow cytometer.
2.3.6

Hemolytic activity
An equal concentration of S-component (HlgA, HlgC, LukE, LukS) and F-component

(HlgB, LukD, LukF) at 250 nM was added to 2% whole blood diluted in PBS and incubated for
1 hour. Hemolytic activity was indicated by reduced RBC sedimentation.
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2.3.7

Statistical analysis
Statistical significance was calculated using analysis of variance (ANOVA) with Tukey’s

honestly significant difference post hoc test for multiple comparison. All statistical analyses were
performed using GrapadPrism (Ver 7.05).
2.4
2.4.1

Results
Cloning, expression, and purification of recombinant staphylococcal cytotoxins
In Gram positive bacteria, a secreted protein has an N-terminal signal peptide which is

recognized by SecB of the Sec-dependent secretory system and guides the protein into the
SecYEG channel at the cytoplasmic membrane where the signal peptidase (Spase) cleaves the
signal peptide and releases the protein outside the cell. Importantly, Gram positive bacterial cell
wall does not contain LPS. These features allow expression and secretion of proteins into the
culture supernate without LPS contamination. For this purpose, we amplified the promoter and
signal peptide of the eta gene and in-frame fused it with the mature form of cytotoxin genes (hla,
hlgA, hlgB, hlgC, lukD, lukE, lukF, lukS) by SOEing PCR which were then cloned into the
multicloning site in the modified pMK4 plasmid containing 6X histidine sequence as shown in
Figure 2.1.
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Figure 2.1

Schematic illustration and results of SOEing PCR

(A) Schematic illustration of SOEing PCR; (B) Amplification of the promoter and signal peptide sequence of the eta
gene from S. aureus UT0003 (Lane 1) and the mature staphylococcal cytotoxin genes from S. aureus LAC LukD
(Lane 2) and joining of the promoter and signal peptide sequence of the eta gene with the mature staphylococcal
cytotoxin gene (LukD) by SOEing PCR (Lane 3).

Recombinant staphylococcal cytotoxins were expressed from S. aureus RF122 toxin free
strain in which staphylococcal cytotoxin genes (Hla, Hlb, HlgABC, LukAB, LukED, LukMF’)
and 7 staphylococcal superantigen genes (SEC, TSST-1, SEG, SEI, SEM, SEN, SEO) were
deleted by homologous recombination to prevent contamination of known staphylococcal toxins.
Analysis of the culture supernates showed very high expression of recombinant protein as
indicated by the thick protein bands corresponding to the expected size of staphylococcal
cytotoxins (Figure 2.2A). These proteins were easily purified using Ni-affinity column
chromatography (Figure 2.2B).
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Figure 2.2

Expression and purification of recombinant cytotoxins

(A) The culture supernates of S. aureus RF122 toxin free strain harboring pOS1 plasmid cloned with a
cytotoxin gene were precipitated with 10% TCA and analyzed by SDS-PAGE. M: molecular standard, lane
1: pOS1 vector control, lane 2: HlgA, lane 3: HlgC, lane 4: LukE, lane 5: LukS, lane 6: HlgB, lane 7:
LukD, lane 8: LukF, lane 9: Hla; (B) Purification results of recombinant cytotoxins using a Ni-column. M:
molecular standard, lane 1: HlgA, lane 2: HlgC, lane 3: LukE, lane 4: LukS, lane 5: HlgB, lane 6, LukD,
lane 7: LukF, lane 8: Hla.

2.4.2

Cytotoxicity of recombinant staphylococcal cytolytic toxins
Although we used a S. aureus strain devoid of all known staphylococcal toxins, it is

possible that uncharacterized toxins may remain in the strain. To verify recombinant
staphylococcal cytotoxins purified from the affinity column chromatography are not
contaminated with any other uncharacterized staphylococcal cytotoxins, whole human
leukocytes were incubated with a very high concentration (500 nM) of a single F- or Scomponent of bi-component leucocidin. Since the cytotoxicity of bi-component leucocidin
requires the presence of both F- and S-component of leucocidin to form cognate and noncognate
oligomers, a single F- or S-component of leucocidin would not be cytotoxic unless contaminated
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with unknown cytotoxins. As shown in Figure 2.3, incubation with a single F- or S-component of
recombinant leucocidin did not lead to any cytotoxicity, while incubation with a pair of LukSFPV recombinant cytotoxin caused significant cytotoxicity. These results demonstrated that
recombinant staphylococcal cytotoxins expressed and purified from S. aureus RF122 toxin-free
strain were highly pure and not contaminated with any unknown staphylococcal cytotoxins.

Figure 2.3

Assessing the purity of recombinant staphylococcal cytotoxins

A single component of bi-component leucocidins (F-component or S-component) at 500 nM was incubated with
human whole leukocytes for 1 hour. The cytotoxicity was assessed by measuring the release of LDH in the culture
supernate. Data shown are the mean ± SEM combined from three experiments. Asterisk indicates statistical
significance compared to the cell only control (student t-test, p<0.001)

To determine the cytotoxicity of cognate and noncognate pairs of bi-component
leucocidins and α-hemolysin in a dose dependent manner, human PMNs or PBMCs were
incubated with a serial dilution of an equal concentration of F- and S-component of leucocidin
ranging from 0.1 to 500 nM for 1 hour. Human PMNs were highly susceptible to the cognate and
noncognate pairs of LukS-PV paired with any F-component of leucocidins, followed by HlgA
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and LukE (Figure 2.4). The cognate pair of HlgCB showed strong cytotoxicity, while the
noncognate pair of HlgC/LukF showed the least cytotoxicity. In general, the noncognate pairs
required higher concentrations to induce similar levels of cytotoxicity caused by the cognate
pairs. Similar to previous reports, Hla did not show strong cytotoxicity toward PMNs [1].

Figure 2.4

The dose dependent cytotoxicity of Hla and cognate and noncognate pairs of bicomponent leucocidins toward human PMNs

Cognate or noncognate pairs of bi-component leucocidins and α-hemolysin ranging from 0.1 to 500 nM were
incubated with human PMNs for 1 hour. The cytotoxicity was assessed by measuring the release of LDH in the
culture supernate. Data shown are the mean ± SEM combined from three experiments. Asterisk indicates statistical
significance of the cytotoxicity caused by cognate pairs compared to noncognate pairs (student t-test, p<0.01).

Toward PBMCs, the cytotoxicity caused by cognate and noncognate pairs of HlgA and
LukE with any F-component of leucocidins was higher than other pairs of bi-component
leucocidins. The HlgAB combination showed highest cytotoxicity, followed by HlgA/LukD >
HlgA/LukF > LukED > LukE/HlgB. Hla showed weaker cytotoxicity than all bi-component
leucocidins.
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Figure 2.5

The dose dependent cytotoxicity of Hla and cognate and noncognate pairs of bicomponent leucocidins toward human PBMCs

Cognate or noncognate pairs of bi-component leucocidins and α-hemolysin ranging from 0.1 to 500 nM were
incubated with human PBMCs for 1 hour. The cytotoxicity was assessed by measuring the release of LDH in the
culture supernate. Data shown are the mean ± SEM combined from three experiments.

2.4.3

Cellular specificity of cytotoxicity caused by staphylococcal cytolytic toxins
Peripheral blood mononuclear cells consist of subpopulations of monocytes, T

lymphocytes, B lymphocytes and NK cells. Each subpopulation has unique functions in host
innate and acquired immunity. For a better understanding of staphylococcal cytotoxin
pathogenesis, we determined the cellular specificity of staphylococcal cytotoxins at leukocyte
subpopulational levels using flow cytometry. For this purpose, peripheral blood mononuclear
cells were incubated with various pairs of F- and S-component of cytolytic toxin at 100 nM for
30 min to induce cell membrane damage but prevent complete lysis for labeling with
fluorescently-conjugated monoclonal antibody (mAb) specific to CD14 (monocytes), CD3 (T
cells), CD4 (CD4 T cells), CD8 (CD8 T cells), CD19 (B cells), and CD56 (NK T cells). The
labeled cells were further incubated with PI which incorporated into the cellular DNA upon
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membrane damage. Results obtained from HlgAB toward CD3+ T cells were shown as
representative data (Figure 2.6). Before incubation with HlgAB, very little CD3+ T cells
(~2.26%) were positive for a PI signal. After incubation with HlgAB at 100 nM for 30 min,
86.4% of CD3+ T cells became positive for a PI signal.

Figure 2.6

Determination of leukocyte subpopulational specificity of staphylococcal
cytotoxin using flow cytometry

Flow cytometry was used to evaluate the percentage of CD3+ T cells within primary human PBMCs and to measure
the degree of cytotoxicity HlgAB caused to CD3+ T cells compared to a cell only control labeled in the same
manner. (A) PBMCs incubated for 30 min were gated from the forward scattering and side scattering channel.; (B)
The PBMCs were incubated with anti-CD3 antibody conjugated with APC and gated with the APC channel.; (C)
Incubated with PI to access membrane damage, the PBMCs were then gated for PI signaling.; (D) Human PBMCs
were incubated with HlgAB at 100 nM for 30 min to induce membrane damage but prevent complete lysis. PBMCs
were gated from the forward scattering and side scattering channel.; (E) Toxin incubated cells were labeled with
anti-CD3 mAb conjugated with APC, and the CD3+ T cells were gated with the APC channel.; (F) CD3+ T cells
with membrane damage were assessed by measuring the percent positive for a PI signal.
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In general, cognate and noncognate pairs of HlgA with any F-component of leucocidins
were highly cytotoxic to all subpopulations of human PBMCs (Figure 2.7). Additionally, LukED
and LukE/HlgB were cytotoxic to CD3+ T cells and CD19+ B cells. Among T cells, CD8+ T
cells were susceptible to LukE/HlgB and LukED, while CD4+ T cells were less susceptible. All
staphylococcal cytotoxins except the pairs of HlgC/LukF and HlgC/LukD were cytotoxic to
CD14+ monocytes. The CD56+ NK cells were more susceptible to cognate and noncognate pairs
of HlgA and LukE paired with any F-component of leucocidins. The CD3+ T cells were highly
susceptible to cognate and noncognate pairs of HlgA with any F-component followed by LukED
and LukE/HlgB. The CD3+ T cells and CD19+ B cells showed similar cellular specificity to
cognate and noncognate pairs of HlgA with any F-component of leucocidins, followed by
LukE/HlgB and LukED. Hla was highly cytotoxic to CD14+ monocytes and CD19+ B cells,
while moderately cytotoxic to other cell types.
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Figure 2.7

Determination of leukocyte subpopulational specificity of staphylococcal
cytotoxin using flow cytometry

Human PBMCs were incubated with Hla or cognate and noncognate pairs of bi-component leucocidins at 100 nM
for 30 min. Cells were labeled with monoclonal antibody specific to CD3, CD4, CD8, CD14, CD19, or CD56
conjugated with APC. Cellular membrane damage was assessed by measuring the percent positive for a PI signal
using flow cytometry.
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2.4.4

Binding of staphylococcal cytolytic toxins to the leukocyte subpopulation
In general, the pore formation by bi-component leucocidins is initiated by binding of the

S- or F-component to their cellular receptors. To determine the binding of S- or F-components to
cellular receptors, staphylococcal cytotoxins were biotinylated and incubated with human PMNs
or PBMCs. Binding of biotinylated staphylococcal cytotoxins to PMNs or PBMCs was probed
by FITC-conjugated streptavidin. All bi-component leucocidins except HlgA highly bind to
human PMNs which indicate cellular receptors for bi-component leucocidins are highly
expressed in human PMNs (Figure 2.8). Toward PBMCs, HlgB and LukF-PV highly bind to all
PBMCs while other bi-component leucocidins bind to a small fraction of PBMCs (Figure 2.9).

Figure 2.8

Binding of bi-component leucocidins to human PMNs

A recombinant bi-component leucocidin was biotinylated and incubated with human PMNs. Binding of biotinylated
toxin to PMNs was probed by FITC-conjugated streptavidin and measured using flow cytometry. The dashed peak
indicates the percentage of cells not bound by protein-antibody, while the solid peak represents the percentage of
cells bound by the protein-antibody.
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Figure 2.9

Binding of bi-component leucocidins to human PBMCs

A recombinant bi-component leucocidin was biotinylated and incubated with human PBMCs. Binding of
biotinylated toxin to PBMCs was probed by FITC-conjugated streptavidin and measured using flow cytometry. The
dashed peak indicates the percentage of cells not bound by protein-antibody, while the solid peak represents the
percentage of cells bound by the protein-antibody.

2.4.5

Hemolytic activity of staphylococcal cytotoxins
RBC hemolysis is a method by which S. aureus releases and utilizes nutrients for

promoting growth. Previous studies demonstrated that HlgAB and LukED can cause lysis of
human RBCs, but hemolytic activity of other cognate and noncognate pairs of bi-component
leucocidins has not been fully known [1,4]. Thus, we determined the hemolytic activity of
cognate and noncognate pairs of bi-component leucocidins. As expected, HlgAB and LukED
clearly showed the lysis of RBCs indicated by the lack of RBC sedimentation (Figure 2.10). In
addition, noncognate pairs of HlgA/LukD, HlgA/LukF, LukE/HlgB, and LukE/LukF also
showed hemolytic activity.
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Figure 2.10

Hemolytic activity of bi-component leucocidins

Cognate and noncognate pairs of bi-component leucocidins at 250 nM (top panel) or single F- or S-components of
bi-component leucocidins (bottom panel) were incubated with human RBC for 1 hour. Lysis of RBCs indicated by
the lack of RBC sedimentation.

2.5

Discussion
In the past decade, there has been significant progress in understanding the cytotoxicity

and cellular specificity of staphylococcal cytotoxins that contribute to the pathobiology of S.
aureus by disarming the host immune response. However, most studies have been focused on
cognate pairs and very little is known about the cytotoxicity and cellular specificity of
noncognate pairs of the bi-component leucocidins. Furthermore, there are discrepancies in the
results of cytotoxicity and cellular specificity which may have resulted from the use of
recombinant proteins contaminated with LPS or from differences in experimental setting such as
concentration of toxins and types of target cells [30]. In this study, we generated recombinant
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staphylococcal cytotoxins expressed in a native S. aureus background to prevent LPS
contamination in the toxin preparation and comprehensively analyzed the cytotoxicity and
cellular specificity of both cognate and noncognate pairs of bi-component leukotoxins and αhemolysin toward human PMNs and PBMCs under uniform toxin concentrations. The protein
expression system established in this study showed a very high level expression of recombinant
staphylococcal cytotoxins to the culture supernate (Fig 2.2) which can be highly purified without
contamination of other staphylococcal proteins as demonstrated by no detectable cytotoxicity
from a single F- or S-component of recombinant leucocidins toward human leukocytes.
Consistent with previous studies, the LukSF-PV appears to be the most cytotoxic to
human PMNs followed by the cognate pairs of HlgAB, LukED, and HlgCB [36]. In addition,
noncognate pairs of bi-component leucocidins except HlgC/F also showed strong cytotoxicity at
250 and 500 nM concentrations. It is generally accepted that the cytotoxicity of the bicomponent leucocidins toward PMNs is initiated by the binding of the S-component to the
specific receptors on the surface of PMN such as CXCR1/2 and C5aR1/2 [33,34]. Our toxin
binding assay showed that not only the S-components, but also the F-components of leucocidins
highly bind to human PMNs which may explain the universal cytotoxicity of the bi-component
leucocidins toward human PMNs. Interestingly, any F-component paired with HlgA showed
strong cytotoxicity in our binding assay; however, HlgA did not bind to human PMNs. Instead,
the F-components (HlgB, LukD, and LukF) of the toxin were found to bind well to human
PMNs. These results suggest that the PMN cytotoxicity mediated by HlgA could be initiated by
the binding of the F-component (HlgB, LukD, and LukF) to the surface receptors on PMNs.
Further study is needed to test this possibility.
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Human PBMCs were more susceptible to HlgA and LukE paired with any F-component
of leucocidins than other toxin pairs. Flow cytometric analysis revealed that CD14+ monocytes
were broadly susceptible to all pairs of bi-component leucocidins and α-hemolysin, while other
PBMC subpopulations showed more tropism to specific pairs of the bi-component leucocidins.
Importantly, all PBMC subpopulations (CD14+, CD3+, CD4+, CD8+, CD19+, CD56+) were
highly susceptible to HlgA paired with any F-component of leucocidins. Additionally, CD56+
NK cells were susceptible to LukE paired with any F-component of leucocidins and LukS/HlgB.
CD8+ T cells and CD19+ B cells were susceptible to LukED and LukE/HlgB. The cytotoxicity
of LukED toward T cells and monocytes/NK cells could be explained by binding of LukED to
CCR5 and CXCR1 on the surface of T cells and monocytes/NK cells, respectively [34,38]. The
cytotoxicity of HlgAB to CD14+ monocytes could be explained by the binding of HlgAB to
CXCR1/2 and CCR2 on human monocytes [34]. However, little is known about how HlgA
paired with any F-component is toxic to other subpopulations of human PBMC. Our toxin
binding assay showed that HlgA only binds to a small fraction of the PBMC subpopulation,
while the F-component of toxins (HlgB and LukF) highly bind to nearly all subpopulations of
PBMCs. The cytotoxicity caused by HlgB and LukF may be initiated by the binding of these
toxins to a common surface receptor on human PBMCs. However, this could not explain the
broad spectrum of cytotoxicity caused by HlgA/LukD which only bind to a small fraction of
human PBMCs. It is possible that HlgA/LukD may form a preassembled dimer, similar to
LukAB, and then binds to the specific receptor on human PBMCs. Further studies will be
necessary to determine this possibility.
A previous study demonstrated that Hla causes rapid plasma membrane permeability of
CD19+ B cells [37]. Consistent with these findings, our results also showed strong cytotoxicity
33

of Hla toward human CD19+ B cells. However, very little is known about the cytotoxicity and
cellular specificity of the bi-component leucocidins toward human B cells. Our results, for the
first time to our knowledge, demonstrated that CD19+ B cells were highly susceptible to HlgA
paired with any F-component and LukED and, to a lesser degree, LukE/HlgB. As previously
mentioned, LukED targets CCR5 for T cell cytotoxicity [2]. Importantly, CCR5 is also highly
expressed on all bone marrow derived human B cells at levels between 150 and 200 molecules
per cell [38]. Thus, it is possible that LukED and LukE/HlgB may also bind to CCR5 to cause
cytotoxicity toward B cells; however, this needs to be experimentally determined.
Previous studies demonstrated the hemolytic activity of HlgAB and LukED which target
the Duffy antigen receptor for chemokines (DARC) and form cation-sensitive pores in the
plasma membrane, resulting in osmotic lysis of human RBCs [3,10]. Additionally, our current
study demonstrated the hemolytic activity of LukE/HlgB and, to a lesser degree, LukE/LukF.
Our current study provides key insights into cognate and noncognate pairs not previously
studied in terms of various leukocyte populations. The most significant finding is that HlgA
paired with HlgB, LukD, and LukF causes cytotoxicity to whole human leukocyte
subpopulations. The gamma hemolysin HlgABC genes are part of the core genome of S. aureus
and are present in more than 99.5% of all clinical isolates. The LukED genes are located in the
pathogenicity island Saβ and are present in 70% of all clinical isolates [17]. On the contrary, the
LukSF-PV genes are located on the temperate phage φSa2 which is highly associated with the
USA300 lineage of S. aureus isolates but accounts for less than 2% of all clinical isolates [17].
Given the conservation in clinical S. aureus isolates and universal cytotoxicity toward whole
leukocyte subpopulations, HlgA paired with HlgB and LukD likely have a broader impact on the
pathogenesis of S. aureus than previously appreciated. Further study is necessary to characterize
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the specific receptor and mechanism of interaction of these toxins for the development of
effective therapeutics.

35

CHAPTER III
OPTIMIZATON OF FAR WESTERN BLOTTING TO INVESTIGATE PROTEIN-PROTEIN
INTERACTION
3.1

Abstract
Many medically important pathogenic bacteria express proteinaceous virulence factors

that interact with receptors expressed in host cells to accomplish their pathogenesis. Thus,
understanding such protein-protein interactions is pivotal to elucidate the mechanism of
pathogenesis and develop successful therapeutics. Far western blotting is a powerful tool to
determine protein-protein interaction by separating and immobilizing the protein of interest on a
membrane which can be probed by biologically tagged target protein. The success of far western
blotting is largely dependent on separating proteins of interest at a high resolution and probing
target protein without non-specific interaction which is often compromised by contamination of
DNA/RNA during the preparation of the protein of interest. In this study, we applied a phenolethanol extraction method to remove DNA/RNA contamination in membrane protein preparation
which highly increased not only the resolution of 2-dimensional separation but also the amount
of membrane proteins extracted from human leukocytes. Denaturation and renaturation of
proteins of interest immobilized on a membrane further increased the specific interaction of the
target protein to the membrane protein. With mass spectrometry analysis, the known human
receptor CD7 was reported, confirming that the correct protein-protein interaction between the
bait protein, galectin-1, and the membrane protein, human primary leukocytes, was identified.
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The method established in this study will provide unprecedented insights to understand
mechanisms of pathogenesis.
3.2

Introduction
Protein-protein interaction is the basis of biological processes in living organisms.

Identification of protein-protein interaction is vital to understand the protein function [39]. There
are several methods to investigate protein-protein interactions. Immunoprecipitation is the most
common method when a specific antibody is available for the protein of interest [40]. Surface
plasmon resonance (SPR) is the most common label-free method which measures the change in
the refractive index of protein solutions due to the protein-protein interaction, compared to a
single protein [41]. A two-hybrid system is based on the activation of a reporter gene such as βgalactosidase on two proteins associated with each other [42,43]. Although these methods are
highly efficient and specific, these methods require soluble proteins and/or specific equipment to
determine protein-protein interaction.
Far western blotting is a method by which protein samples of interest are separated by
electrophoresis and immobilized on a membrane which is probed by a target protein typically
tagged with biotin or fluorescein. The major advantage of far western blotting is that it allows
analysis of naturally expressed specific protein samples such as whole cell lysates or membrane
protein fraction. This is particularly important when investigating the interaction of ligands and
receptors. Receptors are typically membrane proteins extremely difficult to purify as a soluble
form [44-46].
In this study, we optimized the far western blot analysis by purifying membrane proteins
without DNA/RNA contamination for high resolution of 2-dimensional electrophoresis (2DE)
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and reducing non-specific interaction. The established method will be useful to investigate the
function of target proteins in biological processes.
3.3
3.3.1

Materials and methods
Ethics statement and sample preparation
All experiments involving human blood were reviewed and approved by the Institutional

Review Board at Mississippi State University (IRB, 12-041). A written informed consent was
signed by all healthy donors age 18-40 years old. Donor blood was obtained via venipuncture.
Whole leukocytes were isolated by lysing red blood cells using ammonium chloride potassium
(ACK) buffer (Thermo Fisher Scientific). After washing with PBS three times, cells were
counted to 1×108 cells to ensure comparable sample conditions for further analysis. Cell pellets
were stored at – 80 oC until used.
3.3.2

Extraction of membrane proteins
Human leukocytes (1 × 108 cells) were lysed with a cytoplasmic extraction buffer (10

mM HEPES, 60 mM KCl, 1 mM EDTA, 0.075% (v/v) NP-40, 1mM DTT and 1 mM PMSF
adjusted to pH 7.6) on ice for 10 min. The supernate containing cytoplasmic proteins was
removed and the resulting cell pellet was stored at – 80 oC until used.
For membrane protein extraction by a standard method, the cell pellet was resuspended in
a rehydration buffer containing 7M urea, 2M thiolurea, 1% tributyl phosphate (TBP), and 0.2%
immobilized pH gradient (IPG) 3-10 NL for 1 hour at room temperature. After centrifuging at
20,000 ×g for 15 min, the supernate containing membrane proteins were harvested.
For membrane protein extraction by a TRIzol method, the cell pellet was resuspended in
1 mL of TRIzol solution (Invitrogen) and incubated on ice for 10 min. After incubation,
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chloroform (0.2 mL per 1 mL of TRIzol) was added and further incubated on ice for 5 min. After
centrifuging at 12,000 ×g for 15 min at 4 oC, the aqueous phase containing RNA was removed,
and then 0.3 mL of 100% ethanol per 1 mL of TRIzol solution was added to the remaining phase
and incubated on ice for 5 min to precipitate DNA. After centrifuging at 2,000 ×g for 5 min at 4
o

C, the phenol-ethanol phase supernate containing membrane proteins was transferred to a new

tube, and then 1.5 mL of isopropanol was added and incubated on ice for 10 min to precipitate
proteins. After centrifuging at 12,000 ×g for 15 min at 4 oC, protein pellets were resuspended in
0.3 M guanidine hydrochloride in 95% ethanol to remove phenol. After centrifuging at 7,500 ×g
for 5 min at 4 oC, protein pellets were washed with 100 % ethanol. Protein pellets were dried in
air and then resuspended in the rehydration buffer described above.
3.3.3

Two-dimensional electrophoresis
A total amount of membrane protein in the samples was quantified using 2D Quant kit

(GE Healthcare), and 100 µg of protein was loaded on the 3-10 non-linear pH gradient 12 cm
IPG strip (GE Healthcare) by overnight reswelling. Isoelectric focusing was performed using a
Multiphor II electrophoresis system (GE Healthcare) in three running phases (phase I,
250V/0.01h; phase II, 3500V/1.5h; phase III, 3500V/4.5h). The strip was equilibrated in 1%
dithiothreitol followed by 5% iodoacetamide for 10 min in each solution. The two-dimensional
SDS-PAGE was performed using 12.5% polyacrylamide gels in duplicate. One gel was stained
with colloidal Coomassie blue (Pierce), and the other gel was transferred to a PVDF membrane
for far western blot analysis.
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3.3.4

Far western blot analysis
To determine the effect of denaturing and renaturing the proteins in the PVDF membrane

on far western blotting results, one PVDF membrane was incubated in AC buffer (100 mM
NaCl, 20 mM Tris pH7.6, 0.5 mM EDTA, 10% glycerol, 0.1% Tween 20, 2% skim milk) with a
step-wise reduction of the guanidine-HCl concentration from 6 M, 3 M, 1 M, 0.1 M, to 0 M. The
other PVDF membrane was used without denaturation and renaturation. Recombinant Galectin-1
was obtained from Origene and biotinylated using an EZ-Link Sulfo-NHS-Biotin kit (Pierce)
according to the manufacturer’s instruction. The PVDF membrane was incubated with 100 µg of
biotinylated galectin-1 in PBST buffer (4 mM KH2PO4, 16mM Na2HPO4, 115 mM NaCl, pH
7.4) containing 2% skim milk overnight at 4 oC. After washing with PBST buffer, PVDF
membranes were incubated with a streptavidin bead conjugated with horse radish peroxidase
(HRP) in phosphate buffered saline and Tween 20 (PBST) buffer with 2% skim milk. Binding of
biotinylated galectin-1 to membrane protein was detected by enhanced chemiluminescence
(ECL) reagent (Thermo Fisher Scientific) and visualized by x-ray film exposure.
To identify membrane proteins specifically interacting with galectin-1, the protein spots
in the Coomassie stained gel were aligned to the PVDF membrane. Corresponding spots from
the Coomassie stained gel were excised and digested with trypsin (Worthington). Peptide mass
spectra was generated using MALDI-TOF/TOF (ABI4700), and protein identification was
performed using ABI GPS Explorer software V3.5. Deduced peptide sequence was analyzed
using Mascot search engine using the Swiss protein database.
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3.4
3.4.1

Results and discussion
Removal of DNA/RNA by phenol-ethanol phase separation highly increased the
resolution as well as the yield of membrane proteins extracted from primary
human leukocytes.
The ability to extract and solubilize membrane proteins from human leukocytes has been

a major limitation to all proteomic approaches [46]. This is largely due to the enriched genomic
contents such as DNA and RNA in cell lysates which cause co-precipitation of highly insoluble
membrane proteins [47]. To overcome this limitation, we applied phenol-ethanol phase
separation using TRIzol to remove DNA/RNA contamination. A standard membrane protein
extraction method using a high concentration of urea and non-ionic detergent showed poor
resolution in 2 DE separation. By comparison, a treatment with TRIzol highly increased not only
the resolution, but also the number and amount of membrane proteins separated by 2dimensional electrophoresis.
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Figure 3.1

Comparison of the standard urea-based method versus the phenol-ethanol phase
method via 2-dimensional electrophoresis

A total membrane protein extraction of human primary leukocytes by (A) a standard urea-based method or (B)
phenol-ethanol phase method was separated by 2-dimensional electrophoresis.

3.4.2

Denaturing and renaturing membrane proteins immobilized onto the PVDF
membrane highly decreased non-specific binding of biotinylated protein.
Due to their highly hydrophobic transmembrane regions, membrane proteins were

typically extracted in denatured conditions to increase the solubility. However, this limited the
approach to investigate the interaction of the membrane protein with its ligand [47]. For
example, immunoprecipitation or SPR is an effective tool to investigate protein-protein
interactions [48,49]. However, these methods require a soluble form of protein to be tested
[50,51]. Far western blot analysis is particularly advantageous to investigate highly hydrophobic
or insoluble proteins, because these proteins could be separated under denatured conditions and
transferred onto the membrane where they can be renatured for protein function. Renaturation of
protein is commonly accomplished by solubilizing insoluble protein in a chaotropic agent such
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as guanidine hydrochloride (GuHCl) or urea followed by gradually removing chaotropic agent
by dialysis or step-dilutions [52].
To compare the effect of additional denaturation and renaturation of membrane proteins
by GuHCl, membrane protein extracted from primary human leukocytes was separated by 2DE,
transferred to the PVDF membrane, and then used directly for far western blotting or further
incubated with a range of GuHCl from 6 M to 0 M. The PVDF membranes were probed with
biotinylated galectin-1 which is known to interact with various membrane proteins in human
leukocytes. A far western blot without additional denaturation and renaturation with GuHCl
showed very strong non-specific reactions, while an additional denaturation and renaturation by
GuHCl showed highly specific reactions indicated by clean spots precisely corresponding to the
spot in the Coomassie stained gel.
To verify whether the spots identified from an additional denaturation and renaturation by
GuHCl were correctly determined (i.e., the interaction of galectin-1 with human leukocyte
membrane protein), one protein spot was randomly chosen and analyzed by mass spectrometry
for identification. The identity of the protein spot was found to be human CD7 which is known to
interact with galectin-1 [53]. These results suggest that an additional treatment with GuHCl
increased specificity of far western blot analysis.
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Figure 3.2

Comparison of denaturation/renaturation with or without GuHCl and the detection
of a galectin-1 primary human leukocyte membrane protein

A total membrane protein of primary human leukocytes was separated by 2-dimensional electrophoresis and
transferred to a PVDF membrane. (A) PVDF membrane was probed with galectin-1 with or without
denaturation/renaturation with GuHCl.; (B) A far western blot with PVDF membrane denatured/renatured with
GuHCl successfully detected the interaction of galectin-1 with human CD7. Amino acid sequences of human CD7
identified from mass spectrometry were bolded.

Combined, we optimized the protocols to extract and separate membrane proteins from
primary human leukocytes and to increase the specificity of far western blot analysis. The
methods established in this study will provide unprecedented insights to understand protein
function and mechanisms of bacterial pathogenesis.
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CHAPTER IV
HUMAN CORONIN 1A IS A COMMON RECEPTOR FOR STAPHYLOCOCCAL BICOMPONENT LEUCOCIDINS
4.1

Abstract
Staphylococcal bi-component leucocidins are the pore-forming toxins that specifically

kill host leukocytes in a cellular receptor dependent manner. During the past decade, a screening
of natural or a CRISPR-Cas9 guided mutant library of human cells identified chemokine and
cytokine receptors as specific cellular receptors for bi-component leucocidins; however,
expression of these chemokine and cytokine receptors is differentially regulated dependent on
activation status of host cells. Yet, bi-component leucocidins instantly cause cytotoxicity to
human leukocytes, suggesting the presence of a common receptor for bi-component leucocidins
ubiquitously expressed in human leukocytes. In this study, we demonstrated interaction of
human coronin 1A with LukE using a far western blot analysis. Further, lentiviral expression of
human coronin 1A confers susceptibility to not only LukED, but also all pairs of bi-component
leucocidins, except LukAB. A treatment of anti-COR1A antibody successfully neutralized the
cytotoxicity caused by bi-component leucocidins. Our results indicate that human coronin 1A is
a common receptor for bi-component leucocidins. Identification of a common cellular receptor
for bi-component leucocidins will unprecedentedly contribute to the development of effective
therapeutics against S. aureus infections.
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4.2

Introduction
Staphylococcus aureus is a major pathogen that causes significant morbidity and

mortality in humans and animals worldwide. It causes a wide spectrum of diseases ranging from
mild soft tissue and skin infection to severe invasive diseases such as sepsis, endocarditis, and
pneumonia [2,15]. Treatment is complicated by the emergence of multidrug resistance S. aureus
[11]. No effective vaccine has been approved to prevent S. aureus infections [5].
Staphylococcal bi-component leucocidins are a group of virulence factors that
specifically kill host leukocytes and phagocytic cells. As these cells are the central components
of host defense mechanisms against pathogens, staphylococcal bi-component leucocidins have
been considered major virulence factors. Staphylococcal bi-component leucocidins are
comprised of S-components (HlgA, HlgC, LukA, LukE, LukS) and F-components (HlgB, LukB,
LukD, LukF) [1]. Most S. aureus clinical isolates possess multiple cognate pairs of S- and Fcomponent leucocidin genes such as LukAB, LukED, LukSF-PV, and HlgABC. However, pore
formation of bi-component leucocidins can occur not only as cognate pairs of S- and Fcomponents, but also noncognate pairing of any S-component with any F-component [7,17].
With the exception of LukAB, 13 different combinations of bi-component leucocidin pairs are
possible.
Given the important role of bi-component leucocidins in S. aureus pathogenesis, the
identification of host cellular receptors conferring susceptibility and specificity to bi-component
leucocidins has been a hot topic in the research community. Significant progress has been made
in the past decade [10]. Most cellular receptors for leucocidins have been discovered from
characterizing mutant cells naturally resistant to specific leucocidins, screening cell libraries of
human membrane proteins for susceptibility to specific leucocidins, or generating a genome wide
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random mutation using CRISPR-Cas9 to screen for resistance to specific leucocidins [10]. From
these studies, the majority of the receptors targeted by bi-component leucocidins belong to the
family of cytokine and chemokine receptors such as CXCR1/2 for HlgA and LukE, CCR2 for
HlgA, CCR5 for LukE, C5aR1 for HlgC, C5aR2 for LukS, and CD45 for LukF [10]. Aside from
pore forming cytotoxicity, bi-component leucocidins additionally have been found to induce a
proinflammatory response at sublytic doses [1,8]. Thus, it stands to reason that bi-component
leucocidins have evolved to interact with cytokine and chemokine receptors. However,
expression of cytokine and chemokine receptors in leukocytes is differentially regulated in
specific leukocyte subpopulations through particular activating conditions [54]. In contrast to the
time dependent manner of cellular activation, most bi-component leucocidins were instantly
cytotoxic to whole human leukocytes regardless of their activation status. This led us to inquire
whether bi-component leucocidins interact with other common receptors ubiquitously expressed
in human leukocytes.
Here, we report that human coronin 1A is a common receptor for all bi-component
leucocidins, except LukAB. We demonstrated the importance of coronin 1A in cytotoxicity
caused by bi-component leucocidins. Identification of a common cellular receptor for bicomponent leucocidins will unprecedentedly contribute to the development of effective
therapeutics against S. aureus infections.
4.3
4.3.1

Materials and methods
Protection of human subjects statement
All experiments involving human blood were reviewed and approved by the Institutional

Review Board at Mississippi State University (IRB, 12-041). Blood was obtained from de-
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identified participants as well as a written informed consent from healthy volunteers of 18 – 40
years old.
4.3.2

Bacterial strains, culture, and recombinant bi-component leucocidin production
and purification
S. aureus LAC strain was obtained from Dr. Patrick Schlievert at University of Iowa. S.

aureus LAC LukED strain was generated by allelic replacement using homologous
recombination as described elsewhere [35]. For expression of recombinant bi-component
leucocidins, each bi-component leucocidin gene (HlgA, HlgB, HlgC, LukA, LukB, LukD, LukE,
LukF, LukS) was cloned into the pOS1 plasmid between the eta promoter and C-terminal 6Histidine tag. Cloned plasmids were electroporated into S. aureus RF122 toxin free strain
generated by removing all known 11 staphylococcal cytotoxins (Hla, Hlb, HlgABC, LukAB,
LukED, LukMF’) and 7 staphylococcal superantigen genes (SEC, TSST-1, SEG, SEI, SEM,
SEN, SEO) [35]. All strains were cultured in brain heart infusion broth at 37 oC for 18 hours with
shaking at 200 rpm. Culture supernates were collected by centrifugation at 12,000 rpm and
filtered through a 0.45 µM filter. Culture supernates were applied to a Ni-NTA (nickelnitrilotriacetic acid) column using His-Bind Purification Kit (Novagen) as suggested by the
manufacturer. Purity of recombinant bi-component leucocidin was tested by a lack of
cytotoxicity from incubating primary human PMNs with a single recombinant S- or Fcomponent leucocidin. For the far western blot analysis and toxin binding assay, recombinant bicomponent leucocidins were biotinylated using an EZ-Link Sulfo-NHS-Biotin kit (Pierce)
according to the manufacturer’s instruction.
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4.3.3

Isolation of human leukocytes
Whole leukocytes were prepared by lysing red blood cells using ammonium chloride

potassium (ACK) buffer (Thermo Fisher Scientific). Polymorphonuclear cells (PMNs) were
prepared by density gradient centrifugation using PolymorphPrep (Axis-Shield). Peripheral
blood mononuclear cells (PBMCs) were prepared by density gradient centrifugation using
Histopaque-1077 (Sigma-Aldrich). All experiments involving human leukocytes were performed
in RPMI media supplemented with 2% fetal bovine serum (Invitrogen) unless specified
otherwise.
4.3.4

Cytotoxicity assay
Human leukocytes were adjusted to 1×106/ml in RPMI media (Invitrogen). For the bi-

component dose dependent cytotoxicity assay, cells were incubated with pairs of S- and Fcomponents of leucocidin ranging from 100 – 500 nM for 1 hour at 37oC in 5% CO2. For the
time dependent bi-component leucocidin cytotoxicity assay, cells were incubated with pairs of Sand F-components at 100 nM for the indicated time at 37oC in 5% CO2. For the coronin 1A
blocking assay, cells were pre-incubated with 1 µg of anti-coronin 1A mAb (Clone PA-46202)
(Thermo Fisher Scientific) for 30 min followed by incubation with bi-component leucocidins.
After incubation, propidium iodide (PI) solution (0.5 mg/ml) was added and further incubated for
15 min at 4 oC. The fluorescence intensity was measured using a SpectraMax (Molecular
Devices) multifunction plate reader with an excitation at 550 nm and emission at 580 nm. The
fluorescence image was taken by the Cytation 5 microplate reader and microscope (BioTek).
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4.3.5

Flow cytometry analysis
To measure expression of human chemokine/cytokine receptor and coronin 1A, human

leukocytes were labeled with CXCR1 mAb (Clone eBio8F1-1-4), CXCR2 mAb (Clone
eBio5E8-C7-F10), CCR5 mAb (Clone BD2D7), and coronin 1A mAb (Clone PA-46202)
(Thermo Fisher Scientific). For surface staining, cells were harvested, washed with FACS buffer
(eBioscience), and stained for 30 min on ice with mAbs. For intracellular staining, cells were
incubated with Brefeldin A for 1 hour and then further fixed and permeabilized with the
Fix/Perm buffer (eBioscience) according to the manufacturer’s instructions. Fixed/permeabilized
cells were stained with mAbs. Stained cells were analyzed using a FACSAria III flow cytometer
(BD Biosciences). Data was analyzed using FlowJo software (Tree Star, Ashland, OR).
Fluorescence minus one (FMO) controls or isotype controls were used to eliminate a nonspecific Ab effect.
4.3.6

Far western blot analysis and mass spectrometry analysis
Membrane proteins of human primary leukocytes were enriched using a FOCUS

Membrane Protein kit (G-Biosciences) and dissolved in rehydration buffer (7 M urea, 2 M
thiolurea, 1% TBP, and 0.2% ampholite 3-10 NL). A total amount of protein was quantified
using 2D Quant kit (GE Healthcare), and 100 µg of protein was loaded on Immobiline pH
gradient strip with non-linear 3-10 pH gradient (GE Healthcare). The first dimension isoelectric
focusing was performed with Multiphor II electrophoresis system (GE Healthcare) in three
running phases (phase I, 250V/0.01h; phase II, 3500V/1.5h; phase III, 3500V/4.5h). The second
dimension SDS-PAGE was performed using 12.5% polyacrylamide gels in duplicate. One gel
was stained with silver nitrate (Pierce) for mass spectrometry analysis. The other gel was
transferred to a PVDF membrane for far western blot analysis.
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The PVDF membrane was denatured and renatured as described previously, followed by
incubating in a blocking solution (2% skim milk) for 1 hour [55]. The PVDF membrane was
probed with a biotinylated LukE (100 µg) in a blocking solution (2% skim milk) for overnight
incubation at 4 oC. After washing three times with a washing buffer (PBS, 0.05% Tween-20), the
PVDF membrane was further incubated with a streptavidin bead conjugated with horse radish
peroxidase (HRP). A specific interaction of biotinylated LukE with human leukocyte membrane
protein was detected by adding enhanced chemiluminescence (ECL) reagent (Thermo Fisher
Scientific) and visualized by x-ray film exposure. The protein spots from the PVDF membrane
were aligned to the corresponding spots in the silver stained gel. The identified spots were
excised and digested with trypsin (Worthington). Peptide mass spectra was generated using
MALDI-TOF/TOF (ABI4700), and protein identification was performed using ABI GPS
Explorer software V3.5. Deduced peptide sequence was analyzed using Mascot search engine
using the Swiss protein database.
4.3.7

Toxin binding assay
HEK293T pLenti-COR1A or HEK293T pLenti-Mock cells were incubated with

biotinylated leucocidin for 30 min. After gentle washing with PBS three times, cells were further
incubated with Streptavidin-FITC Conjugate (eBioscience) for 30 min. After gentle washing
with PBS, cells were fixed with 4% paraformaldehyde/acetone for 15 min. Cells treated with
Streptavidin-FITC conjugate only served as a control. The fluorescence intensity and image were
obtained using Cytation 5 (BioTek).
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4.3.8

Statistical analysis
GraphPad Prism version 7.0 (GraphPad Software) was used for statistical analysis. Two-

tailed paired t-test and unpaired student t-test were employed. Statistically significant p-value is
indicated in each figure description.
4.4
4.4.1

Results
LukED causes cytotoxicity to nearly all primary human leukocytes, but some
human leukocytes do not express cellular receptors for LukED.
Staphylococcal bi-component leucocidins cause cytotoxicity to the cells expressing

specific receptors. Previous studies demonstrated LukED targets CXCR1/2 and CCR5 to cause
human leukocyte lysis [2,10,34]. As shown in Figure 4.1, incubation of primary human
leukocytes with LukED at 500 nM for 15 min resulted in membrane damage to nearly all
primary human leukocytes. However, flow cytometric analysis showed that CXCR1/2 were
highly expressed in primary human PMNs, while CCR5 was expressed in approximately 20% of
PBMCs. These results suggest that there might be additional cellular receptors for LukED
constantly and ubiquitously expressed in primary human leukocytes.
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Figure 4.1

LukED cytotoxicity on human primary leukocytes and the expression of
characterized LukED receptors on the surface of human primary leukocytes

(A) Primary human leukocytes were incubated with LukED at 500 nM for 15 min, followed by PI staining.
Fluorescent signal from incorporation of PI into the cellular DNA via LukED membrane damage was
determined using flow cytometry.; (B) Expression of LukED receptors, CXCR1/2 and CCR5, on the
surface of human leukocytes were determined by flow cytometry.

4.4.2

LukE interacts with human coronin 1A expressed in primary human leukocytes.
To identify additional cellular receptors on primary human leukocytes that interact with

LukED, membrane proteins of primary human leukocytes were separated by 2-dimenional
electrophoresis followed by either blotting to a PVDF membrane or staining with silver nitrate.
The PVDF membrane was incubated with biotinylated LukE protein followed by incubation with
a streptavidin antibody conjugated to HRP. While many protein spots were detected from a silver
stained gel, biotinylated LukE protein specifically interacted with protein spots clustered in four
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different areas (I-IV). The corresponding protein spots from the silver-stained gel were excised
and digested with trypsin. Resulting peptides were analyzed by liquid chromatography mass
spectrometry (LC-MS). Based on molecular weight, isoelectric point, and coverage to whole
protein sequence, the most relevant protein from each spot was determined and summarized in
Figure 4.2. Among these candidates, we selected coronin 1A, because it is exclusively expressed
in hematopoietic cells including neutrophils, macrophages, T cells, B cells, and NK cells which
overlap with the specificity of LukED [1,10, 56-63].
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Figure 4.2

Interaction of LukE and human coronin 1A with primary human leukocyte
membrane protein

(A)
Far western blot analysis of primary human leukocyte membrane protein probed with biotinylated LukE. A
specific interaction between LukE and membrane proteins was detected by a streptavidin bead conjugated with HRP
and visualized by x-ray film exposure. Protein spots from four different areas were detected.; (B) Protein candidates
identified from electrospray ionization-tandem mass spectrometry were further screened based on isoelectric point
and molecular weight.; (C) Based on the expression pattern of human coronin 1A and the cellular specificity of
LukED, human coronin 1A is further characterized. Amino acid sequences of human coronin 1A identified from
mass spectrometry were underscored.

4.4.3

Immunostaining of coronin 1A expressed in HEK293T cells transfected with
pLenti-COR1A and pLenti-Mock.
To demonstrate that LukE targets coronin 1A, we transfected human embryonic kidney

293T (HEK293T) cells with lentivirus containing either the coronin 1A expression plasmid
(pLenti-COR1A) or the vector control (pLenti-Mock). Immunofluorescence staining
demonstrated that HEK293T pLenti-Mock cells do not express coronin 1A, while HEK293T
pLenti-COR1A highly express coronin 1A.
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Figure 4.3

Immunostaining of coronin 1A on transfected cells

HEK293T cells were transfected with a pLenti-COR1A or pLenti-Mock plasmid. Transfected cells were labeled
with human coronin 1A specific polyclonal antibody conjugated with FITC followed by DAPI staining. Expression
of coronin 1A was analyzed by Cytation 5.

4.4.4

Cells expressing coronin 1A become susceptible to LukED.
To determine cells expressing coronin 1A susceptibility to LukE, HEK293T pLenti-

COR1A and HEK293T pLenti-Mock cells were incubated with LukED followed by PI to
monitor membrane damage (Figure 4.4). HEK293T pLenti-COR1A cells incubated with LukED
highly increased the PI signal in a dose- and time-dependent manner, while HEK293T pLentiMock cells did not show any PI signal. Next, we tested whether blocking the interaction of
coronin 1A protects cells from LukED (Figure 4.5). HEK293T pLenti-COR1A cells treated with
polyclonal antibody specific to human coronin 1A were completely protected from LukED,
while HEK293T pLenti-COR1A cells treated with isotype control antibody remained susceptible
to LukED. These results indicate that LukED specifically targets human coronin 1A and induces
cytotoxicity.
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Figure 4.4

Dose-dependent and time-dependent susceptibility of coronin 1A transfected cells
to LukED

(A) HEK293T pLenti-COR1A and HEK293T pLenti-Mock cells were incubated with 100 nM of LukED for 1 hour,
followed by incubation with PI, to prevent complete cell lysis. Phase contrast and PI images were taken by Cytation
5.; (B) To determine LukED dose-dependent cytotoxicity, HEK293T pLenti-COR1A and HEK293T pLenti-Mock
cells were incubated with 100 to 500 nM of LukED for 1 hour. To determine time-dependent cytotoxicity,
HEK293T pLenti-COR1A and HEK293T pLenti-Mock cells were incubated with 100 nM of LukED up to 3 hours.
Data shown are the mean ± S.E.M combined from three experiments. Asterisk indicates statistical significance
(student t test, p<0.01).
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Figure 4.5

Protection of coronin 1A transfected cells by a coronin 1A polyclonal antibody

HEK293T pLenti-COR1A cells were incubated with a polyclonal antibody specific to coronin 1A or an isotype
control antibody for 30 min and then incubated with 100 nM of LukED for 1 hour. (A) The fluorescent signal and
images were taken by Cytation 5.; (B) Fluorescence intensity values for each treatment. Data shown are the mean ±
S.E.M combined from three experiments. Asterisk indicates statistical significance (student t test, p<0.01).

4.4.5

Expression of coronin 1A in primary human leukocytes is extracellular on PMNs
and intracellular for PBMCs.
To investigate the role of coronin 1A in the cytotoxicity of LukED to primary human

leukocytes, we determined expression of coronin 1A in primary human leukocytes using flow
cytometry. Coronin 1A was highly expressed on the surface of primary human PMNs, while it
was intracellularly expressed in primary human PBMCs.
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Figure 4.6

Expression of coronin 1A in primary human leukocytes

For surface labeling, primary human leukocytes were incubated with rabbit polyclonal antibody specific to human
coronin 1A followed by isotype specific FITC-conjugated secondary antibody. For intracellular staining, cells were
fixed and permed with 0.5% (w/v) paraformaldehyde and 0.2% (w/v) saponin and then labeled with the same
antibodies. Labeled cells were analyzed using flow cytometry.

4.4.6

Human coronin 1A is a main receptor targeted by LukED to cause cytotoxicity.
Previous studies demonstrated that LukED targets CXCR1/2 and causes cytotoxicity in

PMNs [34]. To determine the role of CXCR1/2 and coronin 1A in the cytotoxicity caused by
LukED, primary human PMNs were incubated with LukED in the presence of anti-CXCR1/2 Ab
or anti-COR1A Ab or both Abs. As expected, LukED induced very high cytotoxicity. A
treatment with anti-CXCR1/2 Ab significantly reduced the cytotoxicity, but substantial
cytotoxicity was still present. A treatment with anti-COR1A Ab greatly reduced the degree of
cytotoxicity compared to anti-CXCR1/2 Ab treatment which was not significantly different from
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a treatment with both anti-COR1A and anti-CXCR1/2 Abs. These results suggest that coronin
1A might be the major target of LukED to cause cytotoxicity in PMNs.
Previous studies demonstrated that LukED causes cytotoxicity by targeting CCR5
expressed in PBMCs such as macrophages, dendritic cells, and memory T cells [3,10]. Since
coronin 1A was minimally expressed on the surface of PBMCs, it is possible that the cytotoxicity
caused by LukED in primary human PBMCs might be mainly attributed to the interaction of
LukED to CCR5. To test this possibility, primary human PBMCs were incubated with LukED in
the presence of maraviroc (CCR5 antagonist) or anti-COR1A Ab or both. To our surprise, a
treatment with anti-COR1A Ab resulted in much higher reduction of cytotoxicity than a
treatment with maraviroc alone or both anti-COR1A Ab and maraviroc. These results suggest
that coronin 1A play an important role in cytotoxicity caused by LukED toward primary human
PBMCs.
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Figure 4.7

Comparison of LukED cytotoxicity of human primary leukocytes when treated
with LukED receptor antibodies

(A)
Primary human PMNs were incubated with 100 nM of LukED in the presence of anti-coronin 1a Ab (1 µg)
or anti-CXCR1/2 Ab (1 µg) or both Abs.; (B) Primary human PBMCs were incubated with 100 nM of LukED in the
presence of anti-coronin 1a (1 µg) or maraviroc (100 ng/ml) or both. Cytotoxicity caused by LukED was measured
by Cytation 5. Data shown are the mean percentage ± SEM combined from three independent experiments.

4.4.7

A treatment with anti-COR1A Ab protects primary human leukocytes from
cytotoxicity caused by culture supernates prepared from S. aureus LAC wild type
as well as LukED strains.
To investigate the role of coronin 1A in S. aureus pathogenesis, primary human

leukocytes were incubated with the culture supernates from S. aureus LAC wild type and
LukED strains in the presence or absence of anti-COR1A Ab. A culture supernate from S.
aureus LAC wild type caused very strong cytotoxicity to primary human leukocytes. A culture
supernate from S. aureus LukED strain also showed similar cytotoxicity to primary human
leukocytes. This was expected, because S. aureus LukED strain still produced other bi61

component leucocidins such as HlgABC and Panton-Valentine leucocidin (PVL, LukSF-PV)
which are potent toxins to primary human leukocytes. Surprisingly, a treatment of anti-COR1A
Ab significantly reduced the cytotoxicity caused by both culture supernates from S. aureus LAC
wild type and LukED strains. These results suggest that a treatment of anti-COR1A Ab
protected primary human leukocytes from other bi-component leucocidins, indicating coronin
1A might be targeted by other staphylococcal bi-component leucocidins.

Figure 4.8

Treatment effects of anti-COR1A Ab on primary human leukocytes incubated
with culture supernates of S. aureus LAC wild type or LukED strains.

Primary human leukocytes were incubated with culture supernates from S. aureus LAC wild type and LukED
strains for 1 hour followed by incubation with PI. Cytotoxicity was measured using Cytation 5. Asterisk indicates
statistical significance compared to results without anti-COR1A Ab (n=9, student t-test, p<0.001).

4.4.8

HEK293T pLenti-COR1A cells were susceptible to not only LukED, but also all
other pairs of bi-component leucocidins.
To test this possibility, HEK293T pLenti-COR1A cells were incubated with pairs of S-

and F-component of bi-component leucocidins followed by PI. Results showed that HEK293T
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pLenti-COR1A cells were susceptible to not only LukED but also all pairs of F and S-component
of bi-component leucocidins (Figure 4.9). However, HEK293T pLenti-COR1A cells were not
susceptible to Hla. A treatment with anti-COR1A Ab protected HEK293T pLenti-COR1A cells
from all pairs of bi-component leucocidins. These results strongly suggest that human coronin
1A is a common receptor for bi-component leucocidins.

Figure 4.9

HEK293T pLenti-COR1A cell susceptibility to all bi-component leucocidin pairs

HEK293T pLenti-COR1A cells were incubated with an equal concentration (100 nM) of F- (HlgB, LukD, LukF,
LukB) and S-component (HlgA, HlgC, LukE, LukS, LukA) of leucocidins for 1 hour followed by incubation with
PI. (A) Cytotoxicity was measured using Cytation 5.; (B) HEK293T pLenti-COR1A cells were pretreated with antiCOR1A Ab followed by incubation with an equal concentration of F- and S-component of leucocidins for 1 hour.
Representative fluorescence images from LukED, HlgCB, and no toxin control are shown.

4.4.9

All bi-component leucocidins, except HlgA, bound to coronin 1A transfected cells.
To determine the specific interaction of bi-component leucocidin with human coronin

1A, HEK293T pLenti-COR1A cells were incubated with each biotinylated leucocidin followed
by streptavidin-FITC beads. Results showed that all leucocidins, except HlgA, highly bound to
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HEK293T pLenti-COR1A cells (Figure 4.10). By contrast, none of biotinylated leucocidins
bound to HEK293T pLenti-Mock cells (results from LukE are shown as representative data) nor
a streptavidin-FITC bead alone bound to HEK293T pLenti-COR1A cells. These results clearly
indicate that all bi-component leucocidins, except HlgA, specifically interact with human
coronin 1A to induce cytotoxicity.

Figure 4.10

Binding of bi-component leucocidins to HEK293T pLenti-COR1A cells

HEK293T pLenti-COR1A cells were incubated with biotinylated individual bi-component leucocidin followed by
streptavidin-FITC bead. Binding of biotinylated bi-component leucocidin to HEK293T pLenti-COR1A cells was
determined by Cytation 5.
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4.5

Discussion
Despite intensive research for more than a hundred years, S. aureus still represents one of

the most challenging human pathogens. Successful pathogenesis of S. aureus is largely attributed
to a group of redundant virulence factors that commonly assault the host immune system.
Staphylococcal bi-component leucocidins are the most potent toxins that kill entire human
leukocytes, the central players of the host immune response. During the last decade, specific
receptors for bi-component leucocidins have been characterized which gave unprecedented
insights into the pathogenesis of S. aureus as well as frustrations from the difficulties to block all
these diverse interactions [1,4,5,10}. Therefore, it would be highly significant to identify a
common receptor for all bi-component leucocidins or the domain of bi-component leucocidins
commonly interacting with diverse cellular receptor.
Different from previous approaches mentioned above, we employed a function-based
screening method using far western blot analysis which is a powerful tool to investigate proteinprotein interaction [55]. Far western blot analysis revealed that several candidate proteins
interact with LukE. Among them, coronin 1A has a profile matched with our expectation.
Coronin 1A belongs to a family of actin binding proteins that regulate cytokinesis, cell
polarization, migration, and phagocytosis. Coronin 1A is predominantly expressed in leukocytes
[56]. Previous studies demonstrated that it plays an important role in regulating β2 integrin for
PMN trafficking [57], Ca2+ signaling for macrophage phagocytosis [58], and TCR signaling for
T cell activation and trafficking [59]. Mutations in the coronin 1A gene compromise
development, homeostasis, and function of PMNs and T cell, resulting in sustained viral and
bacterial infection [60]. This makes sense for bi-component leucocidins to interact with coronin
1A to compromise the function of PMNs and T cells. We showed that HEK293T pLenti-COR1A
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cells became susceptible to not only LukED but also all other pairs of bi-component leucocidins,
and a treatment of anti-COR1A antibody successfully neutralized cytotoxicity caused by bicomponent leucocidins. These results clearly demonstrated that coronin 1A is a common cellular
receptor for all pairs of bi-component leucocidins except LukAB.
Our microscopic and flow cytometric analysis showed that coronin 1A is highly
expressed on the surface of HEK293T pLenti-COR1A cells and PMNs, respectively, but not on
PBMCs. Instead, PBMCs highly expressed coronin 1A intracellularly. Interestingly, a treatment
of anti-COR1A Ab successfully protected not only PMNs but also primary human PBMCs from
LukED. Furthermore, protection by anti-COR1A Ab treatment was significantly higher than
those by maraviroc blocking CCR5 interaction with LukED. These results suggest that coronin
1A plays an important role in cytotoxicity caused by LukED toward primary human PBMC
despite predominant intracellular expression of coronin 1A. The structure of coronin 1A consists
of an N-terminal region including 7 WD repeats, a central linker, and a C-terminal coiled coil
[59-63]. The N-terminal WD regions form a 7-bladed β propeller which allows coronin 1A
binding to the cortex of plasma membrane. The central linker region has positively charged
residues which allows coronin 1A binding to F-actin [61,62]. With this structure and
extracellular signaling, coronin 1A has the capacity to cause cytoskeletal remodeling via the
connection of the plasma membrane and actin cytoskeleton [62].
Because the eukaryotic cell membrane is a fluid mosaic model, it is possible that coronin
1A might be spatially exposed extracellularly during cytoskeletal remodeling. To support this
notion, a previous study demonstrated that activation of human PBMCs with staphylococcal
superantigen induced T cell membrane protrusion toward antigen presenting cells, where coronin
1A was localized to subcortical region of T cells followed by re-localization toward the contact
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zone with antigen presenting cells [63]. We are currently investigating the effect of
staphylococcal superantigen in cellular localization of coronin 1A.
The current model for bi-component leucocidins to cause cytotoxicity on target cells is
initial binding of an S-component to the cellular receptor, followed by subsequent recruitment of
an F-component [7]. Our toxin binding assay showed that all S- and F-components of
leucocidins, except HlgA, highly bound to HEK293T pLenti-COR1A cells. It is noteworthy that
HlgA/LukF showed strong cytotoxicity despite the fact that HlgA (an S-component) was not able
to bind coronin 1A. Similar to this finding, a previous study demonstrated that LukF-PV
independently binds to CD45 to cause cytotoxicity in human phagocytes [16]. These results
suggest that the molecular interaction of bi-component leucocidins to their cellular receptor is far
more complicated, and the current model needs to be further revised.
There is no doubt that the bi-component leucocidins are the prime targets for
therapeutics against S. aureus infection because of their conservation in all clinical isolates,
potent cytotoxicity to host leukocytes, and modulation of immune responses. A traditional
vaccine approach to neutralize bi-component leucocidins may only be effective when a person
maintains high neutralizing antibody titers, because phagocytic cells such as PMNs and
macrophages have a critical role in antigen presentation for vaccine memory response, yet they
are the most susceptible targets of bi-component leucocidins. Furthermore, the complicated
repertoire of cellular receptors for each bi-component leucocidin makes it extremely difficult to
develop effective therapeutics [5,6,10,14].
In this study, for the first time to the best of our knowledge, we demonstrate coronin 1A
is the common cellular receptor for all pairs of bi-component leucocidins except LukAB.
Importantly, a treatment of anti-coronin 1A Ab significantly reduced cytotoxicity of S. aureus
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culture supernates suggesting an important role of coronin 1A in cytotoxicity caused by bicomponent leucocidins. Structure-based analysis of coronin 1A’s interaction with bi-component
leucocidins will provide rational design strategies for the development of small molecule
inhibitors for anti bi-component leucocidin therapeutics.
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CONCLUSIONS
Because of S. aureus’s increasing prevalence in humans and its resistance to current
antibiotic therapies, it is imperative to gain more insight into the important virulence factors
aiding in the organism’s pathogenesis. Since the initial discovery of leucocidins in 1894,
research efforts to further characterize the structures and functions of the bi-component
leucocidins have equipped us with a better understanding of their role in pathogenesis. However,
as more knowledge is gained, it becomes more apparent that our understanding of how the bicomponent leucocidins interact with the host immune system and their downstream effects is
incomplete. Thus, the objectives of this dissertation were to comprehensively quantify the
cytotoxic effects of the bi-component leucocidins on primary human leukocyte subpopulations
and erythrocytes as well as to further characterize a human leukocyte receptor that interacts with
all classified leucocidins.
To this end, the first objective utilized primary human leukocytes and erythrocytes to
evaluate the degree of cytotoxicity of the bi-component leucocidin cognate and noncognate pairs.
The cells were incubated with leucocidin proteins that were individually expressed and purified
from a S. aureus deletion mutant strain to ensure cytotoxicity from other molecules was
eliminated. Using flow cytometry and specific antibodies to label the leukocyte subpopulations
(i.e., CD3, CD4, CD8, CD14, CD19, and CD56), the degree of cytotoxicity was evaluated by
propidium iodide signaling. The results indicated that all combinations of leucocidins caused
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some degree of cytotoxicity toward PMNs; however, PVL was the most cytotoxic. For the
PBMC subpopulations, HlgA and LukE combinations caused the greatest degree of cytotoxicity.
The PMN binding assay demonstrated that all leucocidins, except HlgA, can bind individually of
their respective S- or F-component. In contrast, the PBMC binding assay revealed that HlgB and
LukS have high affinity, while the other toxins displayed weak affinity. By comprehensively
quantifying the cytotoxic effects of bi-component leucocidins on primary human leukocyte
subpopulations and erythrocytes, the first objective expanded our knowledge of the cellular
targets for leucocidin pore formation.
In turn, to evaluate the protein-protein interaction of primary human leukocytes and the
bi-component leucocidins, the second objective was to optimize the far western blot technique.
As a result, the protocols for the extraction and separation of primary human leukocyte
membrane proteins were improved as well as the specificity for the protein-protein interactions
observed.
Using the developed protocols from the second objective, the third objective aimed to
identify a cellular receptor shared among all bi-component leucocidins. Primary human PMN
and PBMC lysates were baited with individual biotinylated proteins to characterize proteinprotein interactions via far western blotting analysis. Mass spectrometry identified coronin 1A as
a potential receptor for LukE, and transfected HEK293T pLenti-COR1A cells confirmed coronin
1A was a receptor via cytotoxicity, leucocidin binding, and coronin 1A antibody blocking assays.
The studies completed within the third objective revealed that all leucocidin combinations were
cytotoxic to the transfected cells, except LukAB, and all tested individual leucocidins bind to
coronin 1A except HlgA. Thus, targeting coronin 1A as a therapeutic strategy against the bicomponent leucocidin could serve as a viable alternative approach.
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Overall, the objectives of this dissertation enhanced our understanding of the bicomponent leucocidins’ role in pathogenesis and provided a potential therapeutic target to block
their interactions with human leukocytes.
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